Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Flupentixol→

Flupentixol Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
2709-56-0
Molecular formula
C23H25F3N2OS
Molecular weight
434.5 g/mol
Drug class
Thioxanthene antipsychoticdopamine D2 receptor antagonist
Mechanism of action
Antagonises central dopamine D2 receptors and also interacts with other monoamine receptors, reducing dopaminergic signalling associated with psychosis. Low-dose and depot formulations have different clinical uses and duration.
Indications / reported uses
  • Treatment of schizophrenia and other psychotic disorders with oral or depot formulations in countries where authorised
  • Low-dose oral flupentixol has been used for depressive or anxiety symptoms in some jurisdictions, but these indications are not universal and should be assigned only to the specific authorised product

Sources: NHS — Flupentixol · NLM MeSH — Flupentixol · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Flupentixol Environmental Risk Assessment (ERA) (the Flupentixol ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.